NO20052975L - Nye 2',5'-oligoadenylsyreanaloger. - Google Patents

Nye 2',5'-oligoadenylsyreanaloger.

Info

Publication number
NO20052975L
NO20052975L NO20052975A NO20052975A NO20052975L NO 20052975 L NO20052975 L NO 20052975L NO 20052975 A NO20052975 A NO 20052975A NO 20052975 A NO20052975 A NO 20052975A NO 20052975 L NO20052975 L NO 20052975L
Authority
NO
Norway
Prior art keywords
optionally substituted
mercapto
nucleic acid
synthesis
blocked
Prior art date
Application number
NO20052975A
Other languages
English (en)
Other versions
NO20052975D0 (no
Inventor
Makoto Koizumi
Koji Morita
Original Assignee
Sankyo Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32321740&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20052975(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sankyo Co filed Critical Sankyo Co
Publication of NO20052975D0 publication Critical patent/NO20052975D0/no
Publication of NO20052975L publication Critical patent/NO20052975L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Veterinary Medicine (AREA)
  • Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

2-5A-analoger som har den generelle forme1 (1) og farmakologisk akseptable salter der-av: (1) hvor m er 0 eller 1; n er 0-2; R1 er eventuelt substituert C1-6-alkoksy, merkapto, merkapto blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eller eventuelt substituert C1-4-alkyltio; R2, R3, R4, R5 og R6 er hver hydroksyl, hydroksyl blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eventuelt substituert C1-6-alkoksy, merkapto, merkapto blokkert med en beskyttelsesgruppe for syntese av nukleinsyre, eller eventuelt substituert C1-4-alkyltio; R7 er oksygen eller -O(CH2CH2O)q- (hvor q er 2-6) ; R8 er hydrogen, eventuelt substituert C1-6-alkyl eller en 5'-fosforylert oligonukleotidanalog som mangier en hydroksylgruppe pa 5'-fosfatgruppen; og E1, E2, E3 og E4 er hver en naturlig eller modifisert nukleinsyreenhet.
NO20052975A 2002-11-19 2005-06-17 Nye 2',5'-oligoadenylsyreanaloger. NO20052975L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2002334731 2002-11-19
PCT/JP2003/014748 WO2004046161A1 (ja) 2002-11-19 2003-11-19 新規2',5'-オリゴアデニル酸類縁体

Publications (2)

Publication Number Publication Date
NO20052975D0 NO20052975D0 (no) 2005-06-17
NO20052975L true NO20052975L (no) 2005-08-18

Family

ID=32321740

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20052975A NO20052975L (no) 2002-11-19 2005-06-17 Nye 2',5'-oligoadenylsyreanaloger.

Country Status (17)

Country Link
US (2) US7651999B2 (no)
EP (1) EP1568704A4 (no)
KR (1) KR101117998B1 (no)
CN (1) CN1738829B (no)
AU (1) AU2003284578B2 (no)
BR (1) BR0316431A (no)
CA (1) CA2506581C (no)
CO (1) CO5690648A2 (no)
IL (1) IL168475A (no)
MX (1) MXPA05005321A (no)
NO (1) NO20052975L (no)
NZ (1) NZ539979A (no)
PL (1) PL211566B1 (no)
RU (1) RU2311422C2 (no)
TW (1) TWI347948B (no)
WO (1) WO2004046161A1 (no)
ZA (1) ZA200504017B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020055479A1 (en) 2000-01-18 2002-05-09 Cowsert Lex M. Antisense modulation of PTP1B expression
US7179796B2 (en) 2000-01-18 2007-02-20 Isis Pharmaceuticals, Inc. Antisense modulation of PTP1B expression
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions
US20050106101A1 (en) * 2003-10-31 2005-05-19 Ajay Purohit Novel chemical agents comprising an adenosine moiety or an adenosine analog moiety and an imaging moiety and methods of their use
SG162742A1 (en) * 2005-05-18 2010-07-29 Mitsui Chemicals Inc Catalyst for olefin polymerization, method for producing olefin polymer, method for producing propylene copolymer, propylene polymer, propylene polymer composition, and use of those
CA2676822A1 (en) * 2007-01-31 2008-08-07 Alios Biopharma, Inc. 2-5a analogs and their methods of use
US20090181921A1 (en) * 2007-12-21 2009-07-16 Alios Biopharma Inc. 2-5a analogs and their methods of use
WO2009146417A1 (en) * 2008-05-30 2009-12-03 Sigma-Aldrich Co. Compositions and methods for specifically silencing a target nucleic acid
KR101839177B1 (ko) 2011-04-13 2018-03-15 아이오니스 파마수티컬즈, 인코포레이티드 Ｐｔｐｉｂ 발현의 안티센스 조절
TW201402594A (zh) * 2012-06-18 2014-01-16 Daiichi Sankyo Co Ltd 核苷類似物的製造中間體及其製造方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU637975B2 (en) * 1988-06-09 1993-06-17 Temple University - Of The Commonwealth System Of Higher Education Therapeutic uses of 2',5'-oligoadenylate derivatives
RU2131436C1 (ru) * 1990-09-13 1999-06-10 Санофи Резистентные к нуклеазе олигонуклеозиды, способ их получения и резистентный к нуклеазе нуклеозидный димер
JP3781879B2 (ja) 1996-11-18 2006-05-31 武 今西 新規ヌクレオチド類縁体
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
HU228398B1 (en) * 1999-02-12 2013-03-28 Daiichi Sankyo Company Novel nucleosides and oligonucleotide analogues
WO2001022970A1 (en) * 1999-09-29 2001-04-05 The Cleveland Clinic Foundation Therapy with 2-5a and interferon
JP4245837B2 (ja) * 2000-12-21 2009-04-02 第一三共株式会社 ２’，５’−オリゴアデニル酸類縁体
TWI347948B (en) * 2002-11-19 2011-09-01 Sankyo Co Novel 2',5'-oligoadenylic acid compositions

Also Published As

Publication number Publication date
MXPA05005321A (es) 2005-07-25
ZA200504017B (en) 2006-02-22
US7651999B2 (en) 2010-01-26
IL168475A (en) 2010-05-31
PL211566B1 (pl) 2012-05-31
TW200416224A (en) 2004-09-01
AU2003284578B2 (en) 2007-07-05
RU2005115129A (ru) 2006-02-27
PL376926A1 (pl) 2006-01-09
EP1568704A4 (en) 2009-12-02
WO2004046161A1 (ja) 2004-06-03
KR101117998B1 (ko) 2012-04-12
US7994152B2 (en) 2011-08-09
KR20050083891A (ko) 2005-08-26
BR0316431A (pt) 2005-10-11
EP1568704A1 (en) 2005-08-31
CO5690648A2 (es) 2006-10-31
AU2003284578A1 (en) 2004-06-15
CA2506581C (en) 2013-05-28
NZ539979A (en) 2007-05-31
CN1738829A (zh) 2006-02-22
CA2506581A1 (en) 2004-06-03
RU2311422C2 (ru) 2007-11-27
US20100035976A1 (en) 2010-02-11
US20050261235A1 (en) 2005-11-24
CN1738829B (zh) 2012-11-28
NO20052975D0 (no) 2005-06-17
TWI347948B (en) 2011-09-01

Similar Documents

Publication Publication Date Title
NZ513402A (en) Novel nucleosides and oligonucleotide analogues
NO20052975L (no) Nye 2',5'-oligoadenylsyreanaloger.
HUP0101137A2 (hu) Véralvadást gátló savamidin-származékok és gyógyászati alkalmazásuk
CL2004000917A1 (es) Compuestos derivados de tiazol; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de enfermedades mediadas por 3-cinasa de dosfatidilnositol tal como enfermedades respiratorias, alergias, artritis reumatoide, osteoa
HUP0400206A2 (hu) Metalloproteináz inhibitor hatású imidazolidin-dion-származékok, ezek alkalmazása gyógyszerkészítmények előállítására és ezeket tartalmazó gyógyszerkészítmények
UA85583C2 (ru) Применение ротиготина для профилактики и лечения синдрома паркинсона (плюс)
ATE277066T1 (de) Bicyclonucleosid-analoga
UA84460C2 (ru) Применение сульфонилкарбамидов для борьбы с нежелательным ростом растений в культурах бобовых
ECSP066383A (es) Derivados de 5-fenil-4-metil-tiazol-2-il-amina como inhibidores de enzimas de cinasa fosfatidilinositol 3 (pi3) para el tratamiento de enfermedades inflamatorias de las vías respiratorias
BRPI0111222B8 (pt) derivados fosfonados de glicopeptídeo.
GT200600205A (es) Nuevos herbicidas
TR200202200T2 (tr) Glükopiranosiloksibenzilbenzen türevleri, bu türevleri ihtiva eden tıbbi bileşimler ve türevlerin hazırlanması için ara-maddeler.
WO2007118198A8 (en) 2-METHYLENE-1α,25-DIHYDROXY-19,21-DINORVITAMIN D3 ANALOGS AND USES THEREOF
WO2008035207A3 (en) 2-methylene-1alpha-hydroxy-19,21-dinorvitamin d3 analogs and uses thereof
BRPI0413353A (pt) composição farmacêutica contendo droga solúvel em água
BRPI0508047A (pt) derivados de alquilpiperazina-e alquil-homopiperazina-carboxilatos, o respectivo preparo e a respectiva aplicação como inibidores da enzima faah
EA029775B9 (ru) Применение 1,3,5-триазин-2-ил фосфорамидатного соединения в синтезе софосбувира
BRPI0403979A (pt) composições contendo oligossacarìdeos
EA200701406A1 (ru) Приемлемые для лечения вич соединения
BR0307033A (pt) ácidos 3-(imidazolil)-2-aminopropanóicos para o uso como inibidores tafi-a para o tratamento de doenças trombóticas
BRPI0409798A (pt) geração de plantas com teor alterado de óleo
BR9912817A (pt) Composição terapêutica à base de isoflavonóides destinada a ser utilizada no tratamento dos tumores por agentes citotóxicos
TW200724131A (en) Antibacterial 5,5'-disubstituted 3,3'-dialkoxy-2,2'-dihydroxy-1,1'-biphenyl compounds and related methods
DK1848442T3 (da) 2-methylene-19-nor-(20s-24epi)-1alfa,25-dihydroxyvitamine-d2
ATE525386T1 (de) 3'-ethynylcytidinderivat

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application